UNSPSC 51312309: Diphenhydramine hydrochloride

This classification denotes a histamine-1 receptor antagonist and antiemetic agent with the molecular formula C17H21NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TC2D6JAD40, chemically known as 2-(diphenylmethoxy)-n,n-dimethylethylamine hydrochloride but more generally known as diphenhydramine hcl, which bears US NIH Compound Identifier 3100. European Medicines Agency schedules Diphenhydramine hcl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01769MIG.

UNSPSC 51312309 Diphenhydramine hydrochloride, a Commodity code, reflects state and local procurement of pharmaceutical products including antihistamines and emergency medical supplies for community health, public safety, and emergency response programs. State and local governments purchase under this code to stock emergency medical kits, support public health initiatives, and equip first-responder and community health facilities. Issuing bodies span county health departments, state pharmacy benefit programs, multistate cooperative purchasing alliances, and special-purpose health authorities. Recent solicitations show health departments and state HHS agencies treating this code as part of broader pharmaceutical procurement portfolios rather than as standalone antihistamine purchases—opportunities typically bundle multiple drug categories, OTC products, and emergency medical supplies into single contracts with volume commitments across multiple delivery sites.

Recent activity appears concentrated in Florida and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with bids due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities including Oregon, with proposals due March 26, 2026. The Texas Health and Human Services Commission posted Request for Information HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for establishing direct pharmacy benefit arrangements outside traditional PBM and group purchasing organization channels. The code shows modest recent activity with pharmaceutical procurement concentrated within state health agencies and county health departments pursuing volume contracts through cooperative purchasing vehicles and formal competitive bidding.